Rodriguez M, Miller D J
Department of Neurology, Mayo Clinic, Rochester, MN 55905.
Prog Brain Res. 1994;103:343-55. doi: 10.1016/s0079-6123(08)61148-6.
Remyelination by oligodendrocytes is the normal response to injury of the central nervous system following experimental demyelination by toxins and viruses in rodents. By contrast, in immune-mediated myelin disorders such as human MS, Theiler's virus-induced demyelination or EAE, remyelination is incomplete. We have considered two hypotheses to explain why myelin repair is incomplete in these disorders. Hypothesis I is that myelin repair is the normal consequence of primary myelin injury but there are immune factors which prevent its full expression. To test hypothesis I, we depleted T cells in Theiler's virus infected mice with cyclophosphamide or with monoclonal antibodies to CD4, CD8, or immune response gene products (Ia). Enhanced remyelination and proliferation of glial cells was observed in mice depleted of CD4+ or CD8+ T cells. Hypothesis II is that there are immune factors within some demyelinated lesions which, when present, promote new myelin synthesis. We envision these factors to be present in those lesions showing remyelination but absent in those lesions that remain demyelinated. To test hypothesis II, we generated polyclonal immunoglobulins directed against normal CNS antigens. Transfer of immunoglobulins from mice immunized repeatedly with spinal cord homogenate resulted in 4-5-fold enhancement of remyelination in Theiler's virus infected mice. We have also generated a series of monoclonal antibodies directed against normal autoantigens which also promote CNS remyelination. These experiments support the concept that full CNS remyelination is possible in human demyelinating diseases such as MS. Manipulation of the immune response either by inhibiting the function of T cells or by treatment with immunoglobulins (possibly normal autoantibodies) appears to promote remyelination. These experiments provide hope for patients with fixed neurological deficits for whom there are currently no available therapies.
少突胶质细胞的髓鞘再生是啮齿动物经毒素和病毒实验性脱髓鞘后中枢神经系统损伤的正常反应。相比之下,在免疫介导的髓鞘疾病中,如人类多发性硬化症、泰勒氏病毒诱导的脱髓鞘或实验性自身免疫性脑脊髓炎,髓鞘再生并不完全。我们考虑了两种假说来解释这些疾病中髓鞘修复不完全的原因。假说一认为,髓鞘修复是原发性髓鞘损伤的正常结果,但存在免疫因素阻止其充分表达。为了验证假说一,我们用环磷酰胺或针对CD4、CD8或免疫反应基因产物(Ia)的单克隆抗体使感染泰勒氏病毒的小鼠的T细胞耗竭。在CD4+或CD8+T细胞耗竭的小鼠中观察到髓鞘再生增强和神经胶质细胞增殖。假说二认为,在一些脱髓鞘病变中存在免疫因素,这些因素一旦存在就会促进新的髓鞘合成。我们设想这些因素存在于那些显示有髓鞘再生的病变中,而在那些仍为脱髓鞘的病变中不存在。为了验证假说二,我们制备了针对正常中枢神经系统抗原的多克隆免疫球蛋白。将反复用脊髓匀浆免疫的小鼠的免疫球蛋白转移到感染泰勒氏病毒的小鼠中,可使髓鞘再生增强4至5倍。我们还制备了一系列针对正常自身抗原的单克隆抗体,这些抗体也能促进中枢神经系统的髓鞘再生。这些实验支持了这样一种观念,即在人类脱髓鞘疾病如多发性硬化症中,中枢神经系统的完全髓鞘再生是可能的。通过抑制T细胞功能或用免疫球蛋白(可能是正常自身抗体)进行治疗来操纵免疫反应,似乎可以促进髓鞘再生。这些实验为目前尚无有效治疗方法的患有固定神经功能缺损的患者带来了希望。